Daniel Weilenmann

Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial

Raban Jeger, Ahmed Farah, Marc‐Alexander Ohlow et al. · The Lancet · 2018 · 455 citations

Medicine, Cardiology, Pharmacology +16

Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial

Thomas Pilgrim, Dik Heg, Marco Roffi et al. · The Lancet · 2014 · 267 citations

Medicine, Cardiology, Biomaterials +13

Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial

Raban Jeger, Ahmed Farah, Marc‐Alexander Ohlow et al. · The Lancet · 2020 · 265 citations

Medicine, Cardiology, Internal Medicine +16

Spontaneous Coronary Artery Dissection

Sebastian Rogowski, Micha T. Maeder, Daniel Weilenmann et al. · Catheterization and Cardiovascular Interventions · 2015 · 243 citations

Medicine, Cardiology, Surgery +9

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial

Juan F. Iglesias, Olivier Müller, Dik Heg et al. · The Lancet · 2019 · 188 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15